Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase 2 Clinical Trial of Repeated Intratumoral and Cervical Perilymphatic Lerapolturev Injections Versus Lomustine in Recurrent Glioblastoma (GBM)

NCT06177964 is registered in ClinicalTrials.gov with Darell Bigner as lead sponsor.

NCT NCT06177964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06177964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase 2 Clinical Trial of Repeated Intratumoral and Cervical Perilymphatic Lerapolturev Injections Versus Lomustine in Recurrent Glioblastoma (GBM)
Lead sponsor
Darell Bigner
Phase
Phase 2
Overall status
Recruiting
Start date
July 15, 2024
Completion date
February 28, 2029
Enrollment
92 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent supratentorial glioblastoma